Say hello to MassDevice +5, a bite-sized view of the top five medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 5 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Get this in your inbox everyday by subscribing to our newsletters.
5. Abbott’s new contact ablation catheter: Here’s what you need to know
The new TactiCath contact ablation catheter unites EndoSense and St. Jude Medical technologies that Abbott acquired, marrying fiber optics, flexibility and 3D mapping. Read more
4. Medtronic launches DAPT study for Resolute Onyx DES
Medtronic said today that it’s launching a study of dual anti-platelet therapy and its Resolute Onyx drug-eluting stent.
The 2,000-patient study is designed to compare a one-month course of aspirin and an anti-coagulant in conjunction with the Resolute Onyx device or the BioFreedom DES made by Biosensors International. The Resolute Onyx stent is made from a single strand of cobalt alloy, formed into a sinusoidal wave with a radio-opaque core, Medtronic said. Read more
3. Study: Esophageal surgeries with robotic platforms safe and effective
Transchiatal esophagectomy procedures utilizing robotic platforms are “effective and safe” for carefully selected patients, according to a new study from Allina Health hospitals.
The robotic technology platforms can provide operating surgeons with better views during surgery and allow lymph nodes to be removed without additional incisions, according to the study. Read more
2. Abbott extends Alere tender offer
Abbott said today it is extending a tender offer for all outstanding Alere Series B convertible perpetual preferred stock shares at $402 per share.
As part of the offering, Abbott said it will also pay for unpaid dividends to the settlement date of the tender offer in cash, without interest and subject to applicable taxes. Read more
1. Intuitive Surgical board approves 3-for-1 stock split
Intuitive Surgical said that its board of directors approved a 3-for-1 split of the company’s common stock.
The stock split is still subject to shareholder approval, the Sunnyvale, Calif.-based company said, with a special meeting of stockholders slated for September 22. Read more
